Abstract: A sieve guide assembly and a method of fractionation using a sieve guide assembly comprising a circular sieve screen (190) and a sieve guide 310 mountable in a fractionating device, wherein the fractionating device comprises a drive adapted for: (i) in combination with a sieve screen without a sieve guide, inducing a lateral flow of granules defining lateral streamlines 31a.1. 31b.1, 31c.1, 31d.1 and an orbital flow defining orbital streamlines 31a.2. 31b.2, 31c.2, 31d.2, 31d.3 on the sieve screen (190), and (ii) in combination with the sieve guide assembly, inducing a guided lateral flow of granules defining guided lateral streamlines (331.3) and a central guided orbital flow defining central orbital streamlines (331.2) on the sieve screen (190), whereby the sieve guide assembly is adapted to provide a uniform, controlled and effective exposure of the granules to the sieve screen.

Abstract: A drug delivery device for administration to a subject is provided. In some embodiments, the drug delivery device includes a reservoir containing an active pharmaceutical ingredient and a potential energy source. The drug delivery device also includes a trigger operatively associated with the potential energy source, where the trigger is configured to actuate at a predetermined location within the subject. The drug delivery device also includes a rupturable membrane disposed along a flow path extending between the reservoir and an outlet, where the membrane is configured to rupture when the trigger is actuated. Once the trigger is actuated, the potential energy from the potential energy source may be released to expel the active pharmaceutical ingredient in a jet through the outlet.

Abstract: The invention relates to a pre-filled injection device with a non-removable cartridge wherein the drive mechanics comprises a threaded piston rod which is moved helically in a nut secured to a housing structure. During assembly of the injection device it is possible to rotate the nut member to thereby advance the piston rod into a position eliminating any air-gap otherwise occurring between the piston rod and the plunger inside the cartridge.

Abstract: The present invention provides a piston rod displacement mechanism for a pen injection device, comprising: a tubular housing (2) extending along a reference axis and comprising an interior housing surface (3) with a first engagement structure (4), a nut member (5) fixed within the tubular housing (2), a piston rod (15) comprising a first non-self-locking thread (18) having a first thread direction and a first thread pitch and being engaged with the nut member (5), and a second non-self-locking thread (17) superposed on the first non-self-locking thread (18), the second non-self-locking thread (17) having a second thread direction and a second thread pitch, and a dose dial sleeve (20) operable to advance the piston rod (15) in the nut member (5), the dose dial sleeve (20) comprising an exterior sleeve surface (21) with a second engagement structure (24) being in sliding engagement with the first engagement structure (4), and an interior sleeve surface (23) with a third engagement structure (29) being engaged w

Abstract: The present invention relates to semaglutide for use in weight management.

Abstract: A syringe device for ejecting a dose of a medicament, the syringe device comprising: a dose limiting mechanism arranged to interact with a dose ejecting mechanism to prevent ejection of a dose exceeding a set dose, and a safety mechanism, which is arranged such with respect to the dose ejecting mechanism that, if the dose limiting mechanism fails, the safety mechanism prevents ejection of a dose exceeding the set dose.

Abstract: The present invention relates to improved medical therapies for all forms and stages of dementia involving administration of (i) GLP-1 receptor agonists to subjects with metabolic syndrome or (ii) semaglutide.

Abstract: A device, system and method is provided for predicting risk of hypoglycemia and adjusting an insulin medicament dose size for a subject being on pen based multi-daily injections. A first algorithm is provided for computing a first insulin dose size based on a plurality of timestamped blood glucose (BG) measurements and insulin injected dose sizes. A risk prediction module is adapted to, based on machine learning algorithms, predict risk of hypoglycemia based on the timestamped BG measurements and calculate a second insulin dose size resulting in a non-hypoglycemic state. In case the second dose size is lower than the first dose size, the first dose size is automatically adjusted down to the second dose size and communicated as the recommended dose size to the subject.

Abstract: The invention provides methods of detecting transthyretin (TTR) using a capture antibody and a reporter antibody. The capture antibody binds preferentially to misfolded TTR over native tetrameric form of TTR. The capture antibody binds to an epitope within amino acid residues 89-97 or TTR or to an epitope within amino acid residues 101-109 of TTR. 9D5 and 18C5 are examples of suitable capture antibodies. The methods can be used for diagnosing diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis) and for monitoring the efficacy of TTR therapies, among other applications.

Abstract: The present invention relates to improved uses of glucagon-like peptide-1 (GLP-1) peptides in oral therapy.

Abstract: A drug delivery assembly comprising a magnetic indicator and a sensor system is provided. The indicator is arranged to rotate and move axially relative to a housing component and corresponding to a reference axis, the amount of rotation being indicative of the size of an expelled dose amount. The sensor system comprises a sensor component adapted to measure a property of the indicator indicative of a rotational position and/or a rotational movement of the indicator. The sensor component forms part of release assembly adapted to be moved into engagement with a release member to release a set dose, and subsequently to move axially together with indicator.

Abstract: A drug delivery assembly comprising an indicator adapted to move during expelling of a dose amount of drug, the amount of movement being indicative of the size of the expelled dose amount, and electronic tracking sensor circuitry adapted to with pre-determined intervals to change the operative state from a sleep state to a low-power detection state and back to the sleep state. When in the detection state, the electronic sensor circuitry is adapted to detect motion of an activation component, and if motion of the activation component is detected, then change the operative state from the low-power detection state to a high-power measuring state in which the amount of motion of the indicator relative to the tracking means can be determined.

Abstract: The present invention relates to insulin degludec for use in medicine.

Abstract: This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.

Abstract: The invention relates to a novel administration regime useful in the treatment of diseases or conditions where administration of insulin will be of benefit. In particular, the invention relates to a long-acting or ultra-long acting insulin for use in treating a disease or condition where administration of insulin will be of benefit, wherein the administration of said insulin includes or consists of one or more of the following steps: (a) obtaining a first data set of the subject, (b) obtaining a second data set of the subject, (c) obtaining a first data structure of the subject, and (d) obtaining a second data structure of the subject. When a determination is made that the at least first data structure, second data structure, first data set, and second data set collectively do contain the set of evaluation information, the device further includes providing the long-acting or ultra-long-acting insulin dose guidance recommendation.

Abstract: The present invention provides a system (1) comprising: a pen injection device (10) holding a specific type of medicament and comprising a dose expelling mechanism and pen communication means (15), a mobile communication unit (30) comprising mobile communication means (35) adapted to communicate with the pen communication means (15), and a software application program configured to determine a recommended type of medicament to be delivered to a user based on information indicative of a physiological condition of the user, wherein the pen injection device (10) further comprises indication means which in a first state indicates that the dose expelling mechanism is to remain idle and in a second state indicates that the dose expelling mechanism is available for operation, and wherein the mobile communication unit (30) is configured to, via a communication from the mobile communication means (35) to the pen communication means (15), a) prompt a change of state of the indication means from the second state to the

Abstract: The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.

Abstract: A drug delivery assembly comprising a sensor system in combination with an indicator arranged to rotate, the amount of rotation being indicative of the size of an expelled dose amount. The sensor system comprises a sensor assembly adapted to measure a rotational position and/or a rotational movement of the indicator, the sensor assembly comprising a sensor element adapted to be operated at a non-constant sampling frequency. A processor is configured to determine on the basis of measured values from the sensor element rotational position(s) and/or amount of rotational movement of the indicator, as well as rotational speed of the indicator. To optimize energy consumption the processor is configured to dynamically control the sampling frequency in response to the determined rotational speed.

Abstract: The present disclosure provides crystalline solid forms, spray-dried dispersions and pharmaceutical compositions, including solid oral dosage forms, of (S)-1-(5-[2H,3H-[1,4]dioxino[2,3-b]pyridine-7-sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl)-3-hydroxy-2-phenylpropan-1-one (“Compound 1”), and preparation methods thereof.